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Purpose: Methicillin-resistant Staphylococcus aureus (MRSA) is recognized as an 
important cause of not only healthcare-associated pneumonia (HCAP) but also 
community-acquired pneumonia (CAP). We determined the impact of MRSA on 
differences in clinical characteristics, courses, and outcomes between CAP and 
HCAP. Materials and Methods: We conducted a retrospective observational study 
on 78 adult patients admitted with MRSA pneumonia at a university-affiliated ter-
tiary hospital between January 2008 and December 2011. We compared baseline 
characteristics, chest radiographs, treatment outcomes, and drug resistance patterns 
between the CAP and HCAP groups. Results: Of the 78 patients with MRSA pneu-
monia, 57 (73.1%) were HCAP and 21 (26.9%) were CAP. MRSA infection history 
in the previous year (29.8% vs. 14.3%, p=0.244) tended to be more common in 
HCAP than in CAP. Despite similar Pneumonia Severity Index scores (151 in CAP 
vs. 142 in HCAP), intubation rates (38.1% vs. 17.5%; p=0.072) and intensive care 
unit admission (42.9% vs. 22.8%; p=0.095) tended to be higher in the CAP group, 
while 28-day mortality was higher in the HCAP group (14.3% vs. 26.3%; p=0.368), 
although without statistical significance. All patients showed sensitivity to vanco-
mycin and linezolid; meanwhile, HCAP patients showed greater resistance to gen-
tamicin than CAP patients (58.3% vs. 16.6%; p=0.037). The median total hospital 
charges were 6899 American dollars for CAP and 5715 American dollars for 
HCAP (p=0.161). Conclusion: MRSA pneumonia showed significantly differences 
in baseline characteristics, chest radiographs, treatment outcomes, and medical ex-
penses between HCAP and CAP groups.
Key Words:   Pneumonia, methicillin-resistant Staphylococcus aureus, communi-
ty-acquired pneumonia, healthcare-associated pneumonia
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is a well-known cause of 
hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia, repre-
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groups. This study protocol was approved by the Institu-
tional Review Board of Severance Hospital.
Definitions
Pneumonia was defined as the presence of a new infiltrate on 
chest radiograms with at least one of the following symptoms: 
fever or hypothermia, cough with or without sputum, chest 
pain, dyspnea, or altered breath sounds on auscultation.17
CAP and HCAP were defined according to American Tho-
racic Society/Infectious Diseases Society America (ATS/
IDSA) guidelines.18 HCAP included patients with at least 
one of the following criteria: hospitalization within 90 days 
before the pneumonia diagnosis, admission from a nursing 
home or a long-term care facility, infusion therapy such as 
that with intravenous antibiotics, chemotherapy, or wound 
care within 30 days before the pneumonia diagnosis, and/or 
chronic hemodialysis or peritoneal dialysis.18
We defined immunosuppressed patients as those that com-
prised at least one of following: daily treatment with system-
ic corticosteroids (≥15 mg of prednisone/day for more than 1 
month) or combination therapy with low-dose corticosteroids 
and other immunosuppressants (azathioprine, mycopheno-
late, methotrexate, cyclosporine, or cyclophosphamide), se-
ropositivity for human immunodeficiency virus, receipt of a 
solid organ or bone marrow transplant, radiation therapy or 
chemotherapy for an underlying malignancy within 6 months 
prior to hospital admission, or diagnosis with an underlying 
acquired immune deficiency disorder.19
Total hospital charges included all medical expenses dur-
ing hospitalization, except charges for a hospital room.
Microbiological studies
Pathogens from sputum, blood, bronchoalveolar lavage fluid, 
pleural effusion, or lung abscesses were investigated using 
standard microbiological procedures. Blood cultures were 
considered as an etiological diagnosis if there was no other 
infection source for a positive blood culture. Sputum samples 
were cultured using semi-quantitative manner and an etio-
logical diagnosis was confirmed when a predominant micro-
organism was isolated from group 4 or 5 sputum, according 
to Murray and Washington’s grading system.20 MRSA pneu-
monia was defined as pneumonia coinciding with isolation 
of MRSA as the only potential pathogen. The qualitative 
polymerase chain reaction (PCR) amplification of mecA is 
a rapid and sensitive method for detecting MRSA, but cul-
tures were used because of high rate of false positives in 
PCR method.21 VITEK system was used to evaluate mini-
senting 20--40% of infections.1,2 Unlike the previous con-
finement of MRSA to healthcare settings, MRSA has also 
emerged as an important pathogen in non-nosocomial pneu-
monia, comprising up to 20% of healthcare-associated 
pneumonia (HCAP) cases and up to 10% of community-
acquired pneumonia (CAP) cases.3-7
MRSA pneumonia is likely to be severe and life-threaten-
ing, with high mortality, compared with non-MRSA pneu-
monia.8-10 Rapidly progressive necrotizing pneumonia, due to 
community-associated MRSA, is notable for its high mor-
bidity and mortality, even in relatively young and previously 
healthy patients.11 Although treatment of MRSA pneumonia 
is typically universal, starting with glycopeptide antimicrobi-
al therapy, regardless of the source of infection (i.e., hospital- 
or community-acquired) different risk factors, transmission, 
clinical courses, and antibiotic resistance patterns have been 
reported between hospital-acquired (HA-) and community-
acquired MRSA (CA-MRSA) pneumonia.12,13
Recently, HCAP and CAP have garnered greater concern; 
however, the exact incidence of non-nosocomial pneumonia 
with MRSA is difficult to determine. Although there are a 
number of case reports and small case series in the literature, 
there has yet to be any substantial epidemiologic study. 
HCAP has been described as pneumonia more similar to 
HAP than CAP in terms of epidemiological patterns and 
prognosis.14-16 However, the influence of MRSA on the dif-
ferent characteristics of HCAP and CAP is not well-known.
As CAP and HCAP are classified as different types of 
pneumonia, the purpose of this study was to examine the 
incidences of MRSA CAP and MRSA HCAP. We also at-
tempted to determine the impact of MRSA on differences 
in clinical characteristics, treatment outcomes, and medical 
expenses between CAP and HCAP.
MATERIALS AND METHODS
　　　
Study design and subjects 
We conducted a retrospective observational study on adult 
patients (≥20 years old) admitted with MRSA pneumonia at 
Severance Hospital (a university-affiliated tertiary hospital) 
in South Korea between January 2008 and December 2011. 
Among 943 pneumonia patients with identified pathogens, 
78 patients with MRSA pneumonia were included in this 
study. Patients were classified into CAP or HCAP groups. 
We compared baseline characteristics, treatment outcomes, 
medical expenses, and drug resistance patterns between the 
MRSA CAP and HCAP
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poxemia at admission was observed in more than half of 
the patients in both groups (66.7% in MRSA CAP vs. 61.4% 
in MRSA HCAP; p=0.794), while shock (38.1% vs. 21.1%; 
p=0.15) and MRSA bacteremia (28.6% vs. 17.5%; p=0.346) 
tended to occur more in MRSA CAP than in MRSA HCAP. 
Immunosuppressed status (35.1% vs. 19.0%; p=0.269) and 
previous MRSA infection history within 1 year (29.8% vs. 
14.3%; p=0.244) tended to be more common in MRSA 
HCAP than in MRSA CAP, but without statistical signifi-
cance. CURB65 scores and Pneumonia Severity Index scores 
did not differ between the groups.
Chest radiographs
Chest radiograph findings did not differ between the groups. 
Multiple infiltrates were the most common finding in both 
groups (52.4% in MRSA CAP and 40.4% in MRSA HCAP; 
p=0.342) (Table 2). Diffuse bilateral infiltrates tended to be 
more common in HCAP than in CAP (38.6% vs. 23.8%; 
p=0.223). Pleural effusion was observed in about one-fifth 
of patients in both groups, but no empyema was observed.
Antibiotic treatment and clinical outcomes 
Treatments and clinical outcomes of pneumonia patients with 
MRSA CAP and MRSA HCAP are shown in Table 3. Treat-
ment with glycopeptides within 1 day was higher for MRSA 
CAP than for MRSA HCAP, but without statistical signifi-
cance (28.6% vs. 14.0%; p=0.184). Intubation rates (38.1% 
vs. 17.5%; p=0.072) and intensive care unit (ICU) admission 
mum inhibitory concentrations (MICs) of antimicrobial 
agents.
Patients were treated in accordance with ATS/IDSA guide-
lines although the detailed antibiotic regimens were decided 
by the attending physician, taking into consideration patient 
risk factors and the severity of the disease.
Statistics
We conducted univariate analyses with the χ2 test or Fisher’s 
exact test for categorical variables and the Mann-Whitney U 
test for continuous variables. Non-normally distributed vari-
ables are presented as medians (interquartile range). All tests 
were two-sided, and a p value <0.05 was deemed to indicate 
statistical significance. SPSS software (ver. 18.0; SPSS Inc., 
Chicago, IL, USA) was used for all statistical analyses.
RESULTS
 
Incidence of MRSA in culture-positive CAP and HCAP 
during 2008--2011
The total number of hospitalized patients with non-nosoco-
mial culture-positive pneumonia was 943 (496 in CAP, 447 
in HCAP) between January 2008 and December 2011. The 
total numbers of culture-positive CAP and HCAP for each 
year are as follows: 86 and 79 in 2008, 105 and 105 in 2009, 
133 and 108 in 2010, and 172 and 155 in 2011, respectively. 
The incidence of MRSA in non-nosocomial culture-positive 
CAP and HCAP was 4.2% and 12.8% over the 4 years. The 
change in the proportion of MRSA is shown in Fig. 1. While 
the proportion of MRSA in culture-positive CAP increased 
from 2.9% in 2009 to 4.7% in 2011 that in culture-positive 
HCAP fluctuated between 7.6% and 19.4%. MRSA pneu-
monia was observed most frequently in April (16.7%), No-
vember (12.8%), and December (11.5%).
Baseline characteristics
Among the 78 patients with MRSA pneumonia, 21 (26.9%) 
presented with CAP and 57 (73.1%) presented with HCAP. 
Baseline characteristics of the patients with MRSA CAP 
and MRSA HCAP are listed in Table 1. Median ages in the 
MRSA CAP and MRSA HCAP groups were 73 (60.5--77.5) 
and 71 (66.0--79.5) years old, respectively (p=0.491). Males 
were dominant in both groups (76.2% in MRSA CAP vs. 
73.7% in MRSA HCAP; p=1.000) and hypertension was the 
most predominant underlying disease in both groups (52.4% 
in MRSA CAP vs. 57.9% in MRSA HCAP; p=0.798). Hy-
Fig. 1. Proportion of MRSA culture-positive community-acquired pneumonia 
and healthcare-associated pneumonia from 2008 to 2011. The proportions of 
MRSA in culture-positive CAP and HCAP in each year were as follows: 7% 
(6/86) and 10.1% (8/79) in 2008, 2.9% (3/105) and 7.6% (8/105) in 2009, 3.0% 
(4/133) and 19.4% (21/108) in 2010, and 4.7% (8/172) and 12.9% (20/155) in 2011, 
respectively. CAP, community-acquired pneumonia; HCAP, healthcare-asso-
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Drug resistance patterns
Drug resistance patterns of MRSA pathogens in MRSA CAP 
and MRSA HCAP are shown in Table 4. Comparing various 
drugs resistances, MRSA HCAP showed significantly more 
resistance to gentamicin than MRSA CAP (58.3% vs. 16.6%; 
(42.9% vs. 22.8%; p=0.095) tended to be higher in MRSA 
CAP, while 28-day mortality tended to be higher in MRSA 
HCAP (14.3% vs. 26.3%; p=0.368). The median total hospi-
tal charges were 6899 American dollars in MRSA CAP and 
5715 American dollars in MRSA HCAP (p=0.161).
Table 1. Baseline Characteristics of Patients with MRSA CAP and MRSA HCAP*
Baseline characteristics CAP (n=21) HCAP (n=57) p value
Age, yrs           73.0 (60.5--77.5)       71.0 (66.0--79.5) 0.491
Male    16 (76.2) 42 (73.7) 1
Female      5 (23.8) 15 (26.3)
Underlying diseases
    Diabetes mellitus      9 (42.9) 21 (36.8) 0.794
    Chronic lung disease†      4 (19.0) 16 (28.1) 0.562
    Cerebrovascular accident      5 (23.8) 17 (29.8) 0.778
    Renal disease      5 (23.8)   9 (15.8) 0.508
    Hypertension    11 (52.4) 33 (57.9) 0.798
    Cardiovascular disease      5 (23.8) 16 (28.1) 0.781
    Liver disease      3 (14.3) 3 (5.3) 0.335
    Rheumatologic disease    1 (4.8) 2 (3.5) 1
    Malignancy      7 (33.3) 29 (50.9) 0.206
    Solid organ malignancy      5 (23.8) 27 (47.4) 0.073
    Hematological malignancy    2 (9.5) 2 (3.5) 0.292
Clinical manifestations and parameters
    Bloody sputum 0 (0) 1 (1.8) 1
    Confusion (decreased consciousness)      5 (23.8) 12 (21.1) 0.766
    Shock at onset      8 (38.1) 12 (21.1) 0.15
    PaO2 <60 mm Hg, SpO2 <90%, or need 
      for oxygen therapy
   14 (66.7) 35 (61.4) 0.794
    Acute renal failure at onset      4 (19.0)   9 (15.8) 0.74
    Immunosuppressed‡      4 (19.0) 20 (35.1) 0.269
    MRSA history in previous 1 yr      3 (14.3) 17 (29.8) 0.244
    Tube feeding    1 (4.8) 11 (19.3) 0.164
    Intubated in ER      4 (19.0)   7 (12.3) 0.475
Laboratory findings
    White blood cell           12260 (9230--19600)        11340 (7285--14965) 0.168
    Hematocrit <30%      5 (23.8) 16 (28.1) 0.781
    Blood urea nitrogen >30 mg/dL      7 (33.3) 18 (31.6) 1
    Sodium <130 mmol/L      6 (28.6)   9 (15.8) 0.213
    Glucose >250 mg/dL      4 (19.0)   6 (10.5) 0.445
    pH <7.35    2 (9.5) 5 (8.8) 1
Disease severity
    CURB65     2 (1--3)  2 (1--3) 0.856
    Pneumonia Severity Index         151 (129--158)      142 (125--165) 1.000
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; ER, emergency room.
*Data are presented as numbers (percentages) or medians (interquartile range) unless otherwise indicated.
†Chronic lung disease includes asthma, chronic obstructive pulmonary disease, and structural lung diseases, such as bronchiectasis and interstitial lung 
disease.
‡Immunosuppression included the following: 1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than 1 
month or combination therapy with low-dose corticosteroids and other immunosuppressants, including azathioprine, mycophenolate, methotrexate, cy-
closporine, or cyclophosphamide), 2) seropositivity for human immunodeficiency virus, 3) received a solid organ transplant or bone marrow transplant, 4) 
treated with radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission, or 5) an underlying acquired 
immune deficiency disorder.
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gentamicin. However, all MRSA isolates examined showed 
susceptibility to vancomycin and linezolid.
There are several reports on comparisons of CA-MRSA 
and HA-MRSA.22 However, there are few detailed reports 
about MRSA HCAP, because HCAP only recently became 
a defined group, since 2005, and is composed of heteroge-
neous patients with varying severities of illness and differ-
ent reasons for contact with the healthcare environment. 
Previous studies have suggested that the characteristics of 
HCAP are more similar to those of HAP than CAP. Never-
theless, MRSA infection is frequently a fatal illness with 
high mortality, regardless of the origin of infection. Thus, 
we sought to compare the characteristics and clinical out-
comes of MRSA CAP and MRSA HCAP.
In previous studies, incidences of MRSA HCAP and 
MRSA CAP have been reported up to 30.6% and 14.6%, 
respectively.3-5,19,23,24 While the incidence of MRSA HCAP 
fluctuated from 7.6% to 19.4% over the 4 years in our study 
that of MRSA CAP increased since 2009, from 2.9% to 
4.7%. Fluctuations in MRSA HCAP incidence were likely 
associated with local patterns of nosocomial pathogens dur-
ing the period because most of the patients with HCAP had 
experienced repeated exposure to the hospital. The preva-
p=0.037). Ciprofloxacin (78.5% vs. 66.7%; p=0.542) and 
clindamycin (83.9% vs. 61.9%; p=0.079) showed tenden-
cies for more resistance in MRSA HCAP than in MRSA 
CAP. Resistance to rifampicin was observed only in MRSA 
HCAP, with an incidence of 2.7%, and the proportion of re-
sistance to trimethoprim-sulfamethoxazole was also low in 
both groups (4.8% in MRSA CAP and 7.4% in MRSA 
HCAP; p=0.826). All patients showed sensitivity to vanco-
mycin and linezolid. For vancomycin, the MIC was 2 µg/
mL or less in both groups. For linezolid, the MIC was 2 µg/
mL or less in all MRSA CAP cases, while 8.3% (3/36) of 
MRSA HCAP cases showed an MIC of 4 µg/mL or less.
DISCUSSION
We compared clinical characteristics, outcomes, and drug 
resistance patterns between MRSA CAP and MRSA HCAP 
from 2008 to 2011. Baseline characteristics, initial clinical 
manifestations, including radiological findings, disease se-
verity, clinical outcomes, and medical expenses were simi-
lar between the groups. More patients with MRSA HCAP 
tended to show resistance to ciprofloxacin, clindamycin, and 
Table 2. Chest X-Ray Findings in Patients with MRSA CAP and MRSA HCAP*
Chest X-ray findings CAP (n=21) HCAP (n=57) p value
Single infiltrate   6 (28.6) 15 (26.3) 0.842
Multiple infiltrates 11 (52.4) 23 (40.4) 0.342
Diffuse bilateral infiltrate   5 (23.8) 22 (38.6) 0.223
Cavitation   0 (0) 1 (1.8) 0.541
Pleural effusion   4 (19.0) 13 (22.8) 0.721
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus.
*Data are presented as numbers (percentages).
Table 3. Treatment and Clinical Outcomes of Patients with MRSA CAP and MRSA HCAP*
Treatment/clinical outcomes CAP (n=21) HCAP (n=57) p value
Treatment with glycopeptide within 1 day 6 (28.6)   8 (14.0) 0.184
Clinical outcomes
    28-day mortality 3 (14.3) 15 (26.3) 0.368
    Intubation 8 (38.1) 10 (17.5) 0.072
    ICU admission 9 (42.9) 13 (22.8) 0.095
    Duration of ICU stay, days   17.0 (5.0--26.0)       15.0 (12.0--39.0) 0.512
    Duration of hospital stay, days     23.0 (15.5--61.5)       28.0 (16.5--51.5) 0.292
Total hospital charge, American dollars ($)†
    Mean±SD 19060±21868 11752±16330 -
    Median        6899 (4403--27849)          5715 (3058--11877) 0.108
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard devia-
tion; ICU, intensive care unit.
*Data are presented as numbers (percentages) or medians (interquartile range) unless otherwise indicated.
†Total hospital charges included all medical expenses during hospitalization except charges for the hospital room.
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ages of patients in the present study were not remarkably 
young, with an average in the 70 s, likely the result of popu-
lation aging to the point where the level of immunocompro-
mised subjects increased. Moreover, severe illness features of 
high fever and hemoptysis were not frequent, although hypo-
tension was seen in about 40% of MRSA CAP cases. No pa-
tient with MRSA CAP showed cavitation on a chest X-ray.
MRSA HCAP in this study showed characteristics simi-
lar to the previously reported HA-MRSA pneumonia. The 
patients were elderly, with the average age in the 70 s, and 
half of the patients had significant underlying diseases, such 
as malignancies. Moreover, most of the MRSA isolates from 
HCAP showed resistance to multiple antibiotics.22
In this study, we compared MRSA CAP with MRSA 
HCAP. The average age was similar between the groups, 
lence of MRSA CAP in 2008 was as high as 7.0% because 
the overall number of pneumonia cases with culture-posi-
tive pathogens was low due to relatively less effort being de-
voted to detecting atypical pathogens using serological tests. 
Thus, the relative proportion of MRSA was high, compared 
with other periods.
CA-MRSA pneumonia is associated with an influenza-
like prodrome; severe respiratory symptoms with a rapidly 
progressive pneumonia, evolving to acute respiratory dis-
tress syndrome; high fever (body temperature ≥39°C); he-
moptysis; hypotension; leucopenia; and a chest radiograph 
showing multilobar cavitating alveolar infiltrates.1,22 Young 
age has been a remarkable feature of CA-MRSA pneumonia 
in European and US studies.25-27 However, we demonstrated 
different features of MRSA CAP from previous studies. The 
Table 4. Drug Resistance of Patients with MRSA CAP and MRSA HCAP*
Antibiotics CAP (n=21) HCAP (n=57) p value
Arbekacin   0/19 (0)   0/53 (0) 0.658
Ciprofloxacin 14/21 (66.7) 44/56 (78.5) 0.542
Clindamycin 13/21 (61.9) 47/56 (83.9) 0.079
Erythromycin 17/21 (81.0) 52/56 (92.8) 0.329
Fusidic Acid   4/12 (33.3) 21/36 (58.3) 0.417
Gentamicin   2/12 (16.6) 21/36 (58.3) 0.037
Inducible Clindamycin Resistance   3/12 (25.0)   8/36 (22.2) 0.938
Mupirocin   0/12 (0)   1/36 (2.7) 0.922
Nitrofurantoin   0/12 (0)   1/35 (2.8) 1
Oxacillin 12/12 (100) 36/36 (100) 0.794
Cefoxitin Screen (+)† 20/20 (100) 56/56 (100) 0.469
Penicillin G 19/21 (90.5) 54/56 (96.4) 0.487
Quinupristin/dalfopristin   0/20 (0)   0/55 (0) 1
Rifampicin   0/12 (0)   1/36 (2.7) 0.922
Co-trimoxazole   1/21 (4.8)   4/54 (7.4) 0.826
Teicoplanin   0/21 (0)   0/56 (0) 1
Tetracycline 13/21 (61.9) 36/56 (64.2) 0.751
Tigecycline   0/12 (0)   0/36 (0) 0.794
Telithromycin   4/12 (33.3) 23/35 (65.7) 0.149
Vancomycin   0/21 (0)   0/56 (0) 1
    MIC, ≤0.5 µg/mL   5/12 (41.7) 16/35 (45.7)
    ≤1 µg/mL   5/12 (41.7)   9/35 (25.7)
    ≤1.5 µg/mL        0 (0)   1/35 (2.9)
    ≤2 µg/mL   2/12 (16.7)   9/35 (25.7)
Linezolid   0/21 (0)   0/55 (0) 1
    MIC, ≤1 µg/mL   0/12 (0)   1/36 (2.8)
    ≤2 µg/mL 12/12 (100) 32/36 (88.9)
    ≤4 µg/mL   0/12 (0)   3/36 (8.3)
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; MIC, minimum inhibi-
tory concentration.
*Data are presented as numbers (percentages).
†In a previous study, a cefoxitin screen showed higher sensitivity and specificity for detection of methicillin resistance, especially in low-level-resistant S. 
aureus strains.
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ization; they were older than the general population and 
had higher rates of comorbidities. Finally, the sample size 
was small despite a 4-year study period because of the rela-
tively low incidence of MRSA CAP. Significant differences 
may be expected with increased numbers of cases.
In summary, our study presents a comparison of clinical 
characteristics, outcomes, and drug resistance patterns be-
tween MRSA CAP and MRSA HCAP from 2008 to 2011. 
The incidence of MRSA CAP has increased, unlike that of 
MRSA HCAP. Although HCAP should be generally distin-
guished from CAP because of differing clinical features, 
MRSA infection seems to have broken the boundary between 
HCAP and CAP, and the severe, infectious features that 
MRSA possesses may surpass the supposed differences in 
disease severity and characteristics between HCAP and CAP.
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